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ABSTRACT
Aims To characterise clinicopathological features and
clinical outcomes of the genitourinary tract solitary ﬁbrous
tumours, incorporating NAB2-STAT6 gene fusion status.
Methods The presence of the molecular hallmark
NAB2-STAT6 gene fusion and for the deﬁning fusion
partner product STAT6 was assessed in 11 cases of the
genitourinary tract solitary ﬁbrous tumours. NAB2-STAT6
gene fusion analysis was performed using a break-apart
ﬂuorescence in situ hybridisation (FISH) probe using a
probe cocktail with Bacterial artiﬁcial chromosome (BAC)
clones for STAT6 and NAB2.
Results Eleven solitary ﬁbrous tumours were diagnosed
in eight male patients and three female patients with a
mean age of 46 years (range: 11–64 years). Four of the
tumours had malignant histological features, and three
were considered moderate risk for metastasis. With a
mean follow-up time of 61 months, 1 recurred locally and
2 presented at distant metastatic sites. Using a break-
apart FISH probe cocktail, we found the NAB2-STAT6
gene fusion and nuclear STAT6 expression in 58% and
91% of cases, respectively. However, the NAB2-STAT6
fusion status was not correlated with STAT6 expression or
useful in discriminating between malignant histological
features or subsequent clinical outcomes in the
genitourinary solitary ﬁbrous tumours.
Conclusions A subset of solitary ﬁbrous tumours of the
genitourinary tract behaved aggressively. Using a break-
apart FISH probe cocktail, we found the NAB2-STAT6
gene fusion in 64% of cases. However, the NAB2-STAT6
fusion status was not correlated with STAT6 expression or
useful in discriminating between low-risk or high-risk
tumours and subsequent clinical outcomes.
INTRODUCTION
Solitary ﬁbrous tumours are rare spindle cell neo-
plasms—generally arising—from the pleura, but may
also involve extrapleural sites including the genito-
urinary tract.1 The clinical course of this tumour is
largely indolent; however, aggressive malignant soli-
tary ﬁbrous tumours occur in 15–20% of cases, pre-
senting in an insidious manner with aggressive
behaviour.2 The wide spectrum of clinicopathologi-
cal characteristics and considerable heterogeneity of
morphological features found in solitary ﬁbrous
tumours can provide both diagnostic and prognostic
challenges.3 The clinical presentation can be
incidental, associated with mass effect symptoms or
with the Doege-Potter paraneoplastic syndrome with
a presentation related to hypoglycaemia-induced
symptoms due to production of an Insulin-like
growth factor (IGF)2-like growth factor.
4
Recently, research has uncovered a recurrent
intrachromosomal fusion between the NAB2 and
STAT6 genes on chromosome 12q13 in pleural and
extrapleural solitary ﬁbrous tumours.5 6 Further
investigation revealed strong speciﬁcity of the
nuclear staining expression using an immunohisto-
chemical antibody for the fusion product (STAT6).
With regards to fusion studies, different fusion var-
iants may dominate different locations with poten-
tial clinical implications. As such, the biological
behaviour of these neoplasms is related to clinico-
pathological features and may be related to the ana-
tomical site of tumour and the NAB2-STAT6 gene
fusion variants.7 8 For example, it has been sug-
gested that extrathoracic solitary ﬁbrous tumours
behave more aggressively than the pleural counter-
part. In fact, recent comparative gene expression
proﬁles between extrapleural and pleural solitary
ﬁbrous tumours have demonstrated differences in
various discriminatory transcription factor genes
with enhancement of cell cycles.9 Other studies
have examined body site location of solitary ﬁbrous
tumours as a prognostic variable and found unclear
results when analysed as cohorts at pelvic or
abdominal sites.10 11 A similar investigation found
a statistically signiﬁcant incidence of tumour pro-
gression after surgery between extrathoracic and
pleural solitary ﬁbrous tumours, but the magnitude
of effect was small.4 A similar study of head and
neck solitary tumours also reported considerable
heterogeneity among locations, histological patterns
and NAB2-STAT6 gene fusion variants.12
Although these other sites of solitary ﬁbrous
tumours have been characterised, no systematic
studies incorporating similar comparative variables
have evaluated solitary ﬁbrous tumours at the
genitourinary tract. These variables include histo-
logical features, clinicopathological spectra and the
recent hallmark molecular ﬁndings. This retrospect-
ive study is designed to characterise clinicopatholo-
gical features and clinical outcomes of the
genitourinary tract solitary ﬁbrous tumours.
Additionally, we extended the analysis to include
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variables related to the inceptive chromosomal driver including
NAB2-STAT6 gene fusion expression using a novel break-apart
ﬂuorescence in situ hybridisation (FISH) probe.
METHODS AND MATERIALS
Patients and tissue selection
With institutional board review approval, 11 solitary ﬁbrous
tumours of the genitourinary tract were identiﬁed from the
authors’ institutional surgical pathology database from the period
2005 to 2014. Representative H&E-stained slides were reviewed
by a senior genitourinary pathologist (LC), and the most histologi-
cally representative and best preserved formalin-ﬁxed
parafﬁn-embedded block was chosen for each case with 4–5 mm
unstained slides obtained for immunostaining and FISH testing.
Clinicopathological covariates included age at diagnosis,
symptomatology, location of tumour, size of tumour, procedure,
surgical margin status and invasion of surrounding structures at
initial presentation. The outcome variables included
progression-free and disease-free survival. Progression was
deﬁned as local recurrence (tumour involving tumour bed or
scar) or development of metastatic disease at either distant or
local sites.13
Evaluation of histopathological variables
Representative H&E-stained slides along with immunohisto-
chemically stained slides from each case were reviewed by two
pathologists independently in a double-blinded fashion. The
classical morphological features inherent to this entity were sub-
jectively evaluated for each tumour.
Additional histopathological parameters were evaluated in a
quantitative fashion of all available slides of each case to identify
features of malignancy and to assign metastatic risk stratiﬁcation.
Tumours were scored for mitotic ﬁgures, cellularity, nuclear
pleomorphism and presence of necrosis. The absence of necrosis
or haemorrhage was deﬁned as minimal. Mitotic index was cal-
culated per 10 high-power ﬁelds using the highest count of
three to ﬁve areas scored. The most cellular area of the tumour
was scored for cellularity on a 3-point scale: (1) low (tumour
predominately composed of sclerotic collagen bands with scat-
tered, compressed spindle cells), (2) moderate (many areas of
increased cellularity with cells adjacent to one another) and (3)
high (hypercellular tumour with areas of nuclear overlap).
Pleomorphism was scored on a 3-point scale: (1) low (cells
monomorphic with uniform nuclear features), (2) moderate
(increased nuclear pleomorphism, more prominent nucleoli and
rare multinucleated cells) and (3) high (hyperchromatic nuclei
present with foci of marked pleomorphism and bizarre cells).
Necrosis/haemorrhage was scored as minimal (absence, or
<10%) or positive (≥10%).10
The overall risk stratiﬁcation for the tumour was then calcu-
lated using a point system including additional variables of age
and tumour size. Points for age: (<55 (0 point), ≥55 years (1
point)); tumour size (<5 cm (0 point) 5 cm to ≥10 cm (1
point), 10 cm to <15 cm (2 point) and ≥15 cm (3 point)) and
mitotic ﬁgures (0 (0 point), 1–3 (1 point) and ≥4 (2 points))
were as proposed by Demicco et al.10 The tumour was assigned
a low risk (0–2 total points), moderate risk (3–4 total points)
and high risk (5–6 total points).
Cases of solitary ﬁbrous tumours were also categorised as
malignant according to the 2013 WHO classiﬁcation: >4
mitotic ﬁgures per 10 High power ﬁeld (HPF) with or without
necrosis, hypercellularity, atypia or inﬁltrative growth patterns.
We incorporated a strict deﬁnition using the mitotic count as
the deﬁning characteristic.14 15
Immunohistochemistry
Two pathologists independently evaluated the stained slides for
nuclear STAT6 expression in a blinded manner. The immunohis-
tochemical nuclear expression for STAT6 was quantiﬁed using
the method presented by Akaike et al:7 negative, <5% of cells
with nuclear staining; focally positive, 5–50% of cells with
nuclear staining; and diffusely positive, >50% of cells with
nuclear staining. Expression of CD34 (prediluted, clone
QBEnd-10, DAKO, Carpinteria, California, USA) and bcl-2
(prediluted, clone 124, DAKO) were also assessed in this
fashion. Immunohistochemical staining was performed using the
avidin-biotin complex technique, as previously described.
Primary rabbit monoclonal antibodies were used for the evalu-
ation of STAT6 expression (1:1000 dilution, clone sc-621, Santa
Cruz Biotechnology, Santa Cruz, California, USA).16
NAB2-STAT6 fusion gene analysis
Testing for NAB2-STAT6 fusion by FISH was performed on 4 mm
sections of the corresponding formalin-ﬁxed, parafﬁn-embedded
tissue. The FISH assays were performed according to a previously
described protocol.17 18 The slides were deparafﬁnised and treated
with 0.1 mmol of citrate buffer (pH 6.0) (Zymed, San Francisco,
California, USA) at 95°C for 10 min. The tissue was then digested
with 400 mL of pepsin (5 mg/mL in 0.01N Hydrochloric acid
(HCL) with 0.9% NaCl; Sigma, St Louis, Missouri, USA) at 37°C
for 40 min in a humidiﬁed chamber. The STAT6 split-apart probe
is a cocktail composed of downstream sequence of ATAT6-Green
and 146K upstream of STAT6-Orange (Empire genomics, Buffalo,
New York, USA). The probes were diluted with tDenHyb2 to a
ratio of 1:25. The slides were denatured at 80°C for 10 min and
hybridised at 37°C overnight. The slides were washed twice with
0.1×Saline-sodium citrate (SSC)/1.5 moles urea solution at 45°C
for 20 min each. The slides were then washed with 2×SSC and
2×SSC/0.1% NP40 each for 10 min at 45°C. The slides were
counterstained with 4, 6-diamidino-2-phenylindole (DAPI)
(Insitus Biotechnologies, Albuquerque, New Mexico, USA). The
slides were examined with a Zeiss Axioplan 2 microscope (Ziess,
Gottingen, Germany) using the following ﬁlters: SP-100 DAPI,
MF-101 for Spectrum Green and Gold 31003 for Spectrum
Orange (Chroma, Brattleboro, Vermont, USA). The slides were
analysed with Isis software (MetaSystem, Belmont, Massachusetts,
USA). Four sequential focus stacks with 0.3 mm intervals were
acquired. The Isis software then integrated the stacks automatically
into a single image in order to reduce thickness-related artefacts.
Evaluation and analysis of the cases were carried out by two
pathologists independently. Between 100 and 200 non-
overlapping cancer cell nuclei were evaluated for each case.
Preparations were considered valid if >90% of the cells showed
bright signals. The inversion fusion of NAB2-STAT6 can generate
sequences of 400 Kb between orange and green probes. Such
reversion is manifested by either split-apart orange and yellow
signal or deletion of either an orange or a yellow signal with an
intact orange-yellow signal pair in a tumour cell (ﬁgure 1). A signal
pattern showing two closely approximated orange-yellow signals
was interpreted as a wild type. Conversely, a separate (split)
orange-yellow signal with distance greater than two average signal
diameters, or loss of yellow signal was interpreted as a
NAB2-STAT6 rearrangement, as illustrated in ﬁgure 1. A
NAB2-STAT6 rearrangement was considered positive if ≥10% of
analysed cells showed either a split of one set of red-green signals
with distance greater than two signal widths and/or if loss of one
green signal occurred per Abbott Molecular scoring criteria for
Anaplastic lymphoma kinase (ALK).19–21
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RESULTS
Clinical characteristics and outcomes
The study cohort consisted of eight men and three women
(table 1). The age at diagnosis ranged from 11 years to 64 years
with a mean (median) of 46 (50) years. The majority of subjects
(5 of 7 with available history) presented with symptoms that
related to tumour mass effect on adjacent organs leading to
abdominal pain, early satiety and irritative voiding symptoms.
The patient in case 7 presented with hypoglycaemic symptoms
compatible with the solitary ﬁbrous tumour-related
Doege-Potter paraneoplastic syndrome.
The locations of the genitourinary solitary ﬁbrous tumours
were as follows: kidney (n=4), bladder (n=3), prostate (n=2),
adrenal gland (n=1) and testis (n=1). The tumours ranged in
size from 2.0 cm to 9.0 cm with a mean (median) of 4.7 (3.5)
cm. Four tumours (cases 1, 3, 8 and 10) involved locally adja-
cent organs at the time of presentation (including liver, soft
tissue and vascular structures). The surgical extirpation consisted
of wide surgical resection of the organ, tumour and the invest-
ing structures. Final surgical margins were negative in cases
where assessment was possible. True surgical margins could not
be assessed for two bladder solitary ﬁbrous tumours that were
removed by transurethral resection instead of partial cystectomy;
presumably, complete resection was targeted (table 1).
Clinical progression occurred in three patients at periods of
12–72 months after surgical resection; the mean time to disease
progression was 46 months (median, range: 54, 12–72 months,
respectively). Progression occurred as loc-regional recurrence in
Figure 1 Schematic of the STAT6 split-apart ﬂuorescence in situ hybridisation (FISH) probe design. The orange probe recognises the STAT6 30
sequence and the yellow probe recognises the STAT6 upstream sequence. The red-yellow probes have a distance of 146 Kb in the wild type. The
NAB2-STAT6 fusion by inversion generates a sequence roughly 400 Kb, which manifested as break-apart orange and yellow signals; or loss of a
yellow signal with the presence of intact red-yellow signal pair.
Table 1 Clinicopathological variables and clinical outcomes of 11 cases of solitary fibrous tumours of the genitourinary tract
Case
Age/gender
(years) Symptoms Organ
Tumour size
(cm) Margins
Follow-up
(months) Outcome
Recurrence
(months)
Metastasis
(months)
1 59/M Weight loss Kidney 8.0 Negative 56 DOD 54 54
2 50/M No Kidney 3.5 Negative 22 NED N/A N/A
3 64/F Unknown Kidney 2.8 Negative 60 NED N/A N/A
4 29/F Unknown Kidney 2.0 Negative LT F/U N/A N/A N/A
5 60/M No Prostate 6.0 Negative 81 NED N/A N/A
6 60/M Urinary
obstruction
Prostate 7.0 Negative 60 NED N/A N/A
7 33/F Hypoglycaemia Bladder 3.5 N/A 63 NED N/A N/A
8 41/M Urinary
obstruction
Bladder 5.7 Negative 132 AWD 72 130
9 11/M Unknown Bladder 2.2 N/A 12 AWD 12 N/A
10 58/M Abdominal pain Adrenal
gland
9.0 Negative 60 N/A N/A N/A
11 38/M Unknown Testis 2.1 Unknown LT F/U N/A N/A N/A
AWD, alive with disease; DOD, dead of disease; LT F/U, lost to follow-up; N/A, not applicable; NED, no evidence of disease.
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one patient and metastasis in two patients. Patients with no evi-
dence of disease after resection had a similar mean follow-up
period of those who progressed: 58 months (median, range: 60,
22–81 months, respectively; table 1).
The solitary ﬁbrous tumours which progressed after resection
tended to have more histological malignant features than those
without progression (including >4 mitotic ﬁgures per 10 HPF
and hypercellularity). The patients with disease progression also
met criteria for ‘moderate metastatic risk’ (according to the
prognostic model proposed by Demicco et al10) (table 2). As
aforementioned, this model risk stratiﬁes on tumour size, age
and mitotic activity. Excluding case 9, these patients tended to
be older, had larger tumours and had more malignant features
than those in the ‘low metastatic risk’ cohort. The histological
features associated with aggressive biological behaviour were
similar to those reported for extrathoracic solitary ﬁbrous
tumours.10 Moreover, there was local involvement of surround-
ing organs in two of three tumours which progressed after
resection. Similar relationships between local involvement of
surrounding organs and disease recurrence have also been
reported in other extrathoracic sites.4
Histopathology
Grossly, the tumours had a white, myxoid-like appearance and
were well circumscribed (ﬁgure 2A). Histologically, most of the
tumours showed typical features of solitary ﬁbrous tumours with
alternating hypocellular and hypercellular areas of spindle cells
(ﬁgure 2B).2 Pseudocystic changes were identiﬁed in several
cases, and small areas of haemorrhage and necrosis were seen in
two cases (<10% of the area). Case 11 had a prominent myxoid
stroma with considerable heterogeneous distribution in degree of
cellularity. The majority (7 of 11, 64%) had high cellularity with
clustering cells and minimal intertwined sclerotic collagenous
bands. Figure 3 illustrates a renal solitary ﬁbrous tumour with
aggressive features (case 1). Quantitative assessment of pleo-
morphism among tumours was skewed towards moderate and
low (high, moderate and low in 18%, 45% and 36%, respect-
ively).10 The mitotic rate ranged from 0 to 6 mitotic ﬁgures per
10 HPF, and only 33% of tumours displayed mitotic activity
(table 2 and ﬁgure 3). Haemangiopericytoma-like vessels with
thin vascular walls were present in all cases except case 11 which
was highly collagenous and partially disrupted secondary to the
operative procedure.
All tumours showed positive expression of CD34. The
tumours also showed positive expression of bcl-2 in 9 out of 11
cases (table 2).
NAB2-STAT6 gene fusion and STAT6 immunohistochemistry
findings
Seven of 11 tumours (64%) showed the NAB2-STAT6 fusion using
FISH methodology (table 2, ﬁgure 2D). There was a relatively
uniform and diffuse nuclear expression of STAT6 in 10 of 11 cases
(ﬁgure 2C). One case (case 9) did not show nuclear expression;
however, FISH test for NAB2-STAT6 fusion gene was positive.
There was no correlation between NAB2-STAT6 gene fusion
and malignant histological features of tumours or metastatic risk
classiﬁcation. In addition, there was no correlation between
NAB2-STAT6 gene fusion and clinical outcomes, individual genito-
urinary organs, age or gender. There were no apparent relation-
ships between NAB2-STAT6 gene fusion presence and positive
STAT6 nuclear expression in the cohort. In other words, no clini-
copathological or histological variable was related to positive
nuclear STAT6 expression and absentNAB2-STAT6 gene fusion.
DISCUSSION
In this retrospective study, the clinicopathological characteristics
and disease-related outcomes were examined in a cohort of 11
patients with the genitourinary tract solitary ﬁbrous tumours.
The individual organs were represented in the cohort as
follows: kidney (n=4), bladder (n=3), prostate (n=2), adrenal
gland (n=1) and testis (n=1). To the best of our knowledge,
there are no other similar studies that have examined the genito-
urinary solitary ﬁbrous tumours in a systematic fashion. An
understanding of solitary ﬁbrous tumours at this extrapleural
site has become increasingly relevant with the discovery of the
molecular hallmark NAB2-STAT6 gene fusion. Such genetic
aberrations may improve diagnostic and prognostic accuracy and
may foster elucidation of additional molecular mechanisms
involved in tumorigenesis.2 13 16 22
The results of this study show that the individual morpho-
logical and immunohistochemical features of the genitourinary
solitary ﬁbrous tumours are similar to reported features of other
extrathoracic and pleural solitary ﬁbrous tumours. Furthermore,
the results demonstrate similar relationships between clinico-
pathological features and biological behaviour at the different
tumour locations.4 11 For example, aggressive behaviour of the
genitourinary solitary ﬁbrous tumours were related to similar
Table 2 Genetic and histopathological findings of 11 cases of solitary fibrous tumours of the genitourinary tract
Case
NAB2-STAT6 gene
fusion
Nuclear
STAT6 CD34 Bcl-2
Mitotic count
(per 10 HPF)
Cellularity
(1–3)
Pleomorphism
(1–3)
Malignant
features
Risk* (low,
moderate, high)
1 Positive Positive Positive Positive 4 2 2 Yes Moderate
2 Positive Positive Positive Positive 0 3 1 No Low
3 Negative Positive Positive Positive 0 3 2 No Low
4 Negative Positive Positive Negative 0 3 2 No Low
5 Positive Positive Positive Positive 0 3 3 No Low
6 Negative Positive Positive Positive 0 1 1 No Low
7 Positive Positive Positive Positive 0 2 1 No Low
8 Positive Positive Positive Positive 4 3 3 Yes Moderate
9 Positive Negative Positive Negative 6 3 2 Yes Low
10 Positive Positive Positive Positive 5 3 2 Yes Moderate
11 Negative Positive Positive Positive 0 1 1 No Low
*Risk: Corresponding to metastatic risk category using methods proposed by Demicco et al.10
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variables as those found at other locations including tumour size
(>10 cm), older age and malignant histological features. In this
study, malignant biological behaviour was similar to other body
site solitary ﬁbrous tumours (non-actuarial 5-year disease-related
progression of 30%). Clinical presentation (especially the
unique IGF-2 related paraneoplastic syndrome) and gender were
also similar to other locations of solitary ﬁbrous tumours.4 11
Due to the rarity of the genitourinary solitary ﬁbrous tumours,
there are few single institutional series to compare the clinical
behaviour and related variables of solitary ﬁbrous tumours of
individual genitourinary organs. The comparison must be made
with case series comprised of the few published tumours; unfor-
tunately, this method of comparison introduces considerable
error related to selection bias, recall bias and absence of complete
clinicopathological variables. A single institution study of pros-
tate solitary ﬁbrous tumours identiﬁed malignant features but
found no recurrence over a follow-up of 1–10 years.23 Our cases
of prostatic solitary ﬁbrous tumours in this study are similar to
published cases/series: large tumours (6–7 cm), older patients
and few malignant histological features.1 23–25
A comparison of the four kidney solitary ﬁbrous tumours in
our series between a large compilation renal solitary ﬁbrous
tumours pooled from the literature (n=36) shows a similarly
wide range of tumour sizes, malignant features and a 10–15%
recurrence rate.26 An additional study of renal solitary ﬁbrous
tumours (n=46) also reported many of the same clinicopatholo-
gical features found in the cases of this study.27 In these published
studies, however, variables related to malignant clinical behaviour
were histological (mitotic activity, pleomorphism and cellularity).
These studies did not examine tumour size, age or local involve-
ment of other structures. Moreover, the NAB2-STAT6 gene
fusion presence and STAT6 nuclear expression were not exam-
ined.26 28 These genetic features may also have implications
related to studies of molecular interactions of NAB2 and EGR1
and their involvement in chronic kidney disease and tumorigen-
esis of solitary ﬁbrous tumours by acquisition of complex
genomic proﬁles. This mechanism of acquisition of oncogenes
has been studied in other dedifferentiated solitary ﬁbrous
tumours.26 29–31 Ongoing studies examining other downstream
aberrations in the tumorigenesis of solitary ﬁbrous tumours
appear promising for individual molecular identiﬁcation.7 29
In this study, two of three bladder solitary ﬁbrous tumours
(cases 7 and 8) had malignant features and large tumour size,
yet showed no recurrence after 60 months and 132 months.
The few published cases of bladder solitary ﬁbrous tumours
(n=17) reported both malignant and bland histological features,
yet no recurrence. These reports did not examine NAB2-STAT6
gene fusion presence or STAT6 nuclear expression. The third
case in this study (case 9) showed a rapid recurrence after
12 months. This behaviour may relate to proposed mechanistic
pathways for development of a malignant solitary ﬁbrous
tumour involving dedifferentiation of a pre-existing benign
tumour and acquisition of additional complex genetic aberra-
tions.32 33 As in other sites, studies are currently expanding the
understanding of other genes overexpressed in solitary ﬁbrous
tumours, which may lead to insight into the mechanisms of pro-
gression and insight into subsequent therapeutic targets.9 32–34
In this study, the lack of agreement between STAT6 immuno-
histochemical staining and NAB2-STAT6 fusion expression by
FISH reﬂects the extensive distribution of break points at the
transcript levels that require several primers for complete ana-
lysis.29 As published, all fusion transcripts contain the ﬁrst two
Figure 2 Solitary ﬁbrous tumours of the genitourinary tract. (A) Typical solitary ﬁbrous tumour gross appearance showing circumscribed, ﬁrm,
homogenous white-to-tan mass. In this case, the solitary ﬁbrous tumour is arising from a kidney (upper left aspect of image). (B) Typical solitary
ﬁbrous tumour morphology with haphazardly arranged spindle cells set in a hyalinised background with multiple small, branching blood vessels; (C)
Nuclear expression of STAT6 seen on immunohistochemical staining (200×); (D) Fluorescence in situ hybridisation (FISH) analysis showing break
apart of the STAT6 (green) and its upstream sequence (orange) suggesting the fusion between NAB2 and STAT6.
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exons of NAB2 and last six exons of STAT6. However, a range
of fusions exist between NAB2 exon4 and STAT6 exon3 and
between NAB2 exon 6 and STAT6 exon 17. Moreover, differen-
tial expression of the 50 part of NAB2 can occur, suggesting that
some solitary ﬁbrous tumours might have fusion transcripts that
require other primers.5 29 The lack of agreement between
STAT6 immunohistochemical staining and NAB2-STAT6 fusion
expression found in this study may result from unique fusions
which still translocate the NAB2 to the nucleus and modulate
STAT6 gene expression (negative NAB2-STAT6 fusion presence
with positive nuclear expression of STAT6).6 29 In fact, investi-
gators have suggested a prognostic relationship between differ-
ent fusion variants and the behaviour of solitary ﬁbrous
tumours. For example, one study found that detected fusion
variants related to particular anatomical subsites of extrathoracic
solitary ﬁbrous tumours.22 Relationships were also examined
between NAB2-STAT6 gene fusion variants, body site location,
age and tumour size, and clinical outcomes of solitary ﬁbrous
tumours. Although the study did not demonstrate signiﬁcant
relationships, it highlights the potential use of fusion variants
for outcome prediction.22 STAT6 immunohistochemistry
probably sufﬁces for diagnostic evaluation of solitary ﬁbr-
ous tumours. Additional studies such as ours have also shown
that the NAB2-STAT6 inversion is not consistently detected by
FISH due to very close proximity of the two genes (overlapping
ends) and in this setting Reverse transcriptase (RT)-PCR is the
preferred method of detection.
Unfortunately, the present study was not designed to examine
the presence and relationships of individual gene fusion variants
and additional studies are needed. Other limitations of this
study are the limited number of subjects in the cohort (inherent
in studies of rare entities). As with any retrospective study there
is also the potential for selection bias, recall bias and potential
impact of unknown confounders. In this study, the effects of
selection and analytical bias were minimised by the blinded
method of tissue selection, blinded FISH and immunohisto-
chemical analyses, and sequential batch analysis method. The
effect of recall bias and confounding variables were minimised
in the current study through centralised specimen procurement,
reporting and subsequent clinical follow-up.
Figure 3 Aggressive solitary ﬁbrous tumour of the genitourinary tract (case 1). (A and B) Solitary ﬁbrous tumour showing aggressive features
(100× and 200×, respectively). The tumour shows moderate degree of cellularity with cells adjacent to each other and limited sclerotic collagen
bands. There is moderate pleomorphism with nucleoli readily visible. A mitotic ﬁgure is displayed in the centre of (B); (C) Nuclear expression of
STAT6 seen on immunohistochemical staining (200×); (D) Fluorescence in situ hybridisation (FISH) analysis showing break apart of the STAT6 (green)
its upstream (orange) signals suggesting NAB2-STAT6 fusion; (E and F) Cytoplasmic expression of CD34 and bcl-2, respectively (200×).
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Our ﬁndings suggest that a subset of solitary ﬁbrous tumours
of the genitourinary tract may behave aggressively. Using a
break-apart FISH probe cocktail, we found the NAB2-STAT6
gene fusion in 64% of cases. However, the NAB2-STAT6 fusion
status was not correlated with STAT6 expression or useful in
discriminating between low-risk or high-risk tumours and subse-
quent clinical outcomes.
Take home messages
▸ Solitary ﬁbrous tumour is a rare lesion in the genitourinary
tract. The diagnosis and prognosis can be challenging as it is
one of a number of spindle cell lesions which share
overlapping immunohistochemical and morphological proﬁles.
▸ Genitourinary tract solitary ﬁbrous tumour can be
characterised by immunohistochemical stains for the
deﬁning fusion partner product STAT6.
▸ A subset of solitary ﬁbrous tumours of the genitourinary
tract tends to be clinically aggressive.
▸ Using a new break-apart ﬂuorescence in situ hybridisation
probe cocktail, we found the NAB2-STAT6 gene fusion in
64% of cases. However, the NAB2-STAT6 fusion status was
not correlated with STAT6 expression or useful in
discriminating between low-risk or high-risk tumours and
subsequent clinical outcomes.
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